Completed PHASE4 INTERVENTIONAL 2-arm NCT00819325

Prevention of Instent Renarrowing With Aggressive Glucose Lowering With Pioglitazone in Diabetic Patients (PPAR-G)

Prevention of Neointimal Proliferation With Aggressive Reduction of Glucose Concentrations (Pioglitazone) Study -- PPAR-G -- An IVUS Pilot Feasibility Study in Type 2 Diabetic Patients.

Sponsor: Nova Scotia Health Research Foundation

Conditions Angina Pectoris Coronary Artery Disease Percutaneous Coronary Intervention Type 2 Diabetes Mellitus

Interventions oral hypoglycemic agents pioglitazone

Updated 4 times since 2017 Last updated: Jan 6, 2009 Started: Aug 31, 2002 Primary completion: Nov 30, 2006 Completion: Mar 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Angina Pectoris and Coronary Artery Disease, this trial is completed. The trial is conducted by Nova Scotia Health Research Foundation and has accumulated 4 data snapshots since 2002. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jan 2017 — Jan 2021 [monthly]

Completed PHASE4

First recorded

Aug 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Nova Scotia Health Research Foundation
Queen Elizabeth II Health Sciences Centre

Data source: Queen Elizabeth II Health Sciences Centre

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Halifax, Canada